LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lyka Labs has filed its Annual Secretarial Compliance Report for FY25, confirming full compliance with SEBI LODR Regulations, Secretarial Standards, and applicable corporate governance norms. The practicing company secretary found no deviations, penalties, or actions taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries during the year. No directors were disqualified, and the statutory auditors did not resign during the review period. Two material events were noted: (1) allotment of 26,00,000 equity shares of Rs. 10 each at a premium of Rs. 129.50 to promoter-group entity Ipca Laboratories on conversion of warrants (16th April 2024), and (2) a fresh application before NCLT Ahmedabad for amalgamation of Lyka Exports Limited with Lyka Labs, with shareholder and creditor meetings directed by NCLT on 23rd January 2025.
This is a routine compliance filing with no adverse findings, so it should not move the stock. However, the warrant conversion strengthened the promoter group's stake via Ipca Labs, and the ongoing Lyka Exports amalgamation could lead to restructuring benefits or simplification of the group structure if approved by NCLT.